Increased muscle mass protects against hypertension and renal injury in obesity

Joshua T. Butcher, James D. Mintz, Sebastian Larion, Shuiqing Qiu, Ling Ruan, David J Fulton, David W Stepp

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background-Obesity compromises cardiometabolic function and is associated with hypertension and chronic kidney disease. Exercise ameliorates these conditions, even without weight loss. Although the mechanisms of exercise’s benefits remain unclear, augmented lean body mass is a suspected mechanism. Myostatin is a potent negative regulator of skeletal muscle mass that is upregulated in obesity and downregulated with exercise. The current study tested the hypothesis that deletion of myostatin would increase muscle mass and reduce blood pressure and kidney injury in obesity. Methods and Results-Myostatin knockout mice were crossed to db/db mice, and metabolic and cardiovascular functions were examined. Deletion of myostatin increased skeletal muscle mass by _50% to 60% without concomitant weight loss or reduction in fat mass. Increased blood pressure in obesity was prevented by the deletion of myostatin, but did not confer additional benefit against salt loading. Kidney injury was evident because of increased albuminuria, which was abolished in obese mice lacking myostatin. Glycosuria, total urine volume, and whole kidney NOX-4 levels were increased in obesity and prevented by myostatin deletion, arguing that increased muscle mass provides a multipronged defense against renal dysfunction in obese mice. Conclusions-These experimental observations suggest that loss of muscle mass is a novel risk factor in obesity-derived cardiovascular dysfunction. Interventions that increase muscle mass, either through exercise or pharmacologically, may help limit cardiovascular disease in obese individuals.

Original languageEnglish (US)
Article numbere009358
JournalJournal of the American Heart Association
Volume7
Issue number16
DOIs
StatePublished - Aug 1 2018

Fingerprint

Myostatin
Renal Hypertension
Obesity
Muscles
Wounds and Injuries
Kidney
Weight Loss
Obese Mice
Skeletal Muscle
Glycosuria
Blood Pressure
Albuminuria
Chronic Renal Insufficiency
Knockout Mice
Cardiovascular Diseases
Down-Regulation
Salts
Fats
Urine
Hypertension

Keywords

  • Hyperglycemia
  • Hypertension
  • Myostatin
  • Nicotinamide-adenine dinucleotide phosphate
  • Oxidase 4
  • Reduced form
  • Skeletal muscle

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Increased muscle mass protects against hypertension and renal injury in obesity. / Butcher, Joshua T.; Mintz, James D.; Larion, Sebastian; Qiu, Shuiqing; Ruan, Ling; Fulton, David J; Stepp, David W.

In: Journal of the American Heart Association, Vol. 7, No. 16, e009358, 01.08.2018.

Research output: Contribution to journalArticle

Butcher, Joshua T. ; Mintz, James D. ; Larion, Sebastian ; Qiu, Shuiqing ; Ruan, Ling ; Fulton, David J ; Stepp, David W. / Increased muscle mass protects against hypertension and renal injury in obesity. In: Journal of the American Heart Association. 2018 ; Vol. 7, No. 16.
@article{8bba0b134aa74caabc6e63955065bd32,
title = "Increased muscle mass protects against hypertension and renal injury in obesity",
abstract = "Background-Obesity compromises cardiometabolic function and is associated with hypertension and chronic kidney disease. Exercise ameliorates these conditions, even without weight loss. Although the mechanisms of exercise’s benefits remain unclear, augmented lean body mass is a suspected mechanism. Myostatin is a potent negative regulator of skeletal muscle mass that is upregulated in obesity and downregulated with exercise. The current study tested the hypothesis that deletion of myostatin would increase muscle mass and reduce blood pressure and kidney injury in obesity. Methods and Results-Myostatin knockout mice were crossed to db/db mice, and metabolic and cardiovascular functions were examined. Deletion of myostatin increased skeletal muscle mass by _50{\%} to 60{\%} without concomitant weight loss or reduction in fat mass. Increased blood pressure in obesity was prevented by the deletion of myostatin, but did not confer additional benefit against salt loading. Kidney injury was evident because of increased albuminuria, which was abolished in obese mice lacking myostatin. Glycosuria, total urine volume, and whole kidney NOX-4 levels were increased in obesity and prevented by myostatin deletion, arguing that increased muscle mass provides a multipronged defense against renal dysfunction in obese mice. Conclusions-These experimental observations suggest that loss of muscle mass is a novel risk factor in obesity-derived cardiovascular dysfunction. Interventions that increase muscle mass, either through exercise or pharmacologically, may help limit cardiovascular disease in obese individuals.",
keywords = "Hyperglycemia, Hypertension, Myostatin, Nicotinamide-adenine dinucleotide phosphate, Oxidase 4, Reduced form, Skeletal muscle",
author = "Butcher, {Joshua T.} and Mintz, {James D.} and Sebastian Larion and Shuiqing Qiu and Ling Ruan and Fulton, {David J} and Stepp, {David W}",
year = "2018",
month = "8",
day = "1",
doi = "10.1161/JAHA.118.009358",
language = "English (US)",
volume = "7",
journal = "Journal of the American Heart Association",
issn = "2047-9980",
publisher = "Wiley-Blackwell",
number = "16",

}

TY - JOUR

T1 - Increased muscle mass protects against hypertension and renal injury in obesity

AU - Butcher, Joshua T.

AU - Mintz, James D.

AU - Larion, Sebastian

AU - Qiu, Shuiqing

AU - Ruan, Ling

AU - Fulton, David J

AU - Stepp, David W

PY - 2018/8/1

Y1 - 2018/8/1

N2 - Background-Obesity compromises cardiometabolic function and is associated with hypertension and chronic kidney disease. Exercise ameliorates these conditions, even without weight loss. Although the mechanisms of exercise’s benefits remain unclear, augmented lean body mass is a suspected mechanism. Myostatin is a potent negative regulator of skeletal muscle mass that is upregulated in obesity and downregulated with exercise. The current study tested the hypothesis that deletion of myostatin would increase muscle mass and reduce blood pressure and kidney injury in obesity. Methods and Results-Myostatin knockout mice were crossed to db/db mice, and metabolic and cardiovascular functions were examined. Deletion of myostatin increased skeletal muscle mass by _50% to 60% without concomitant weight loss or reduction in fat mass. Increased blood pressure in obesity was prevented by the deletion of myostatin, but did not confer additional benefit against salt loading. Kidney injury was evident because of increased albuminuria, which was abolished in obese mice lacking myostatin. Glycosuria, total urine volume, and whole kidney NOX-4 levels were increased in obesity and prevented by myostatin deletion, arguing that increased muscle mass provides a multipronged defense against renal dysfunction in obese mice. Conclusions-These experimental observations suggest that loss of muscle mass is a novel risk factor in obesity-derived cardiovascular dysfunction. Interventions that increase muscle mass, either through exercise or pharmacologically, may help limit cardiovascular disease in obese individuals.

AB - Background-Obesity compromises cardiometabolic function and is associated with hypertension and chronic kidney disease. Exercise ameliorates these conditions, even without weight loss. Although the mechanisms of exercise’s benefits remain unclear, augmented lean body mass is a suspected mechanism. Myostatin is a potent negative regulator of skeletal muscle mass that is upregulated in obesity and downregulated with exercise. The current study tested the hypothesis that deletion of myostatin would increase muscle mass and reduce blood pressure and kidney injury in obesity. Methods and Results-Myostatin knockout mice were crossed to db/db mice, and metabolic and cardiovascular functions were examined. Deletion of myostatin increased skeletal muscle mass by _50% to 60% without concomitant weight loss or reduction in fat mass. Increased blood pressure in obesity was prevented by the deletion of myostatin, but did not confer additional benefit against salt loading. Kidney injury was evident because of increased albuminuria, which was abolished in obese mice lacking myostatin. Glycosuria, total urine volume, and whole kidney NOX-4 levels were increased in obesity and prevented by myostatin deletion, arguing that increased muscle mass provides a multipronged defense against renal dysfunction in obese mice. Conclusions-These experimental observations suggest that loss of muscle mass is a novel risk factor in obesity-derived cardiovascular dysfunction. Interventions that increase muscle mass, either through exercise or pharmacologically, may help limit cardiovascular disease in obese individuals.

KW - Hyperglycemia

KW - Hypertension

KW - Myostatin

KW - Nicotinamide-adenine dinucleotide phosphate

KW - Oxidase 4

KW - Reduced form

KW - Skeletal muscle

UR - http://www.scopus.com/inward/record.url?scp=85052383653&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85052383653&partnerID=8YFLogxK

U2 - 10.1161/JAHA.118.009358

DO - 10.1161/JAHA.118.009358

M3 - Article

VL - 7

JO - Journal of the American Heart Association

JF - Journal of the American Heart Association

SN - 2047-9980

IS - 16

M1 - e009358

ER -